Novartis is paying $1 billion upfront for global rights to PTC Therapeutics’ midphase Huntington's disease program, helping ...
The Phase 1 trial ANQUR, now testing two new doses of the ALS therapy QRL-201, is enrolling patients at 12 sites in Canada and across Europe.
Monday’s agreement comes days after PTC discontinued the development of another asset, utreloxastat, due to disappointing ...
3h
On Monday, PTC Therapeutics, Inc. (NASDAQ:PTCT) signed an exclusive global license and collaboration agreement with Novartis ...
Scientists studied 188 people related to someone with ALS caused by a C9ORF72 mutation to identify markers of disease risk in ...
Support from individual and corporate donors fuels the life-improving work of the ALS Network, formerly ALS Golden West. The ALS Network offers hope and help throughout the ALS community by providing ...
But utreloxastat had little effect on ALS in the phase 2 trial. PTC powered the study to show whether twice-daily oral dosing ...
The Food and Drug Administration (FDA) has not approved stem cell therapy for amyotrophic lateral sclerosis (ALS). However, people could participate in clinical trials involving this ALS treatment.
The groundbreaking physicist not only made a splash by discovering that black holes emit radiation, but also as a pop-culture ...
At the center of a new licensing deal is an experimental medicine, PTC518, which is currently being tested in a roughly ...
MRI is a diagnostic test that doctors use to diagnose and track the progress of amyotrophic lateral sclerosis (ALS). ALS is a progressive disease that damages nerve cells in the brain and spinal cord.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback